P. thor Straten

发表

TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients

T. Schumacher, M. V. van Buuren, G. Kenter, 2012, Oncoimmunology.

Function and dysfunction of CD4+ T cells in the immune response to melanoma

J. Becker, W. Fischer, P. Terheyden, 1999, Cancer Immunology, Immunotherapy.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma*

S. H. van der Burg, J. Castle, H. Rammensee, 2019, Molecular & Cellular Proteomics.

Dissection of T-cell antigen specificity in human melanoma.

T. Schumacher, M. Donia, I. Svane, 2012, Cancer research.

The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens

P. thor Straten, M. Andersen, 2010, Oncotarget.

Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient

I. Svane, S. Hadrup, P. thor Straten, 2007, Cancer Immunology, Immunotherapy.

Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.

J. Becker, L. Pedersen, E. Bröcker, 2001, Cancer research.

Design and validation of conditional ligands for HLA‐B*08:01, HLA‐B*15:01, HLA‐B*35:01, and HLA‐B*44:05

I. Svane, M. Heemskerk, M. Heemskerk, 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion

M. Donia, I. Svane, S. Hadrup, 2012, Cancer Immunology and Immunotherapy.

Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

M. Donia, I. Svane, H. Hendel, 2016, Clinical Cancer Research.

Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.

P. Guldberg, J. Zeuthen, P. thor Straten, 1997, Cancer research.

Melanoma inhibitor of apoptosis protein (ML-IAP) specific cytotoxic T lymphocytes cross-react with an epitope from the auto-antigen SS56.

J. Becker, D. Schrama, P. thor Straten, 2009, The Journal of investigative dermatology.

Characterization of Ex Vivo Expanded Tumor Infiltrating Lymphocytes from Patients with Malignant Melanoma for Clinical Application

I. Svane, P. thor Straten, M. Andersen, 2011, Journal of skin cancer.

Vγ9Vδ2 T Cells Concurrently Kill Cancer Cells and Cross-Present Tumor Antigens

E. Noessner, B. Moser, Ö. Met, 2021, Frontiers in Immunology.

Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction

M. Pedersen, Ö. Met, E. Høgdall, 2017, Oncoimmunology.

Exercise and cancer: from “healthy” to “therapeutic”?

P. thor Straten, M. Idorn, 2017, Cancer Immunology, Immunotherapy.

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.

B. Seliger, T. Schumacher, M. V. van Buuren, 2017, Cancer research.

Targetless T cells in cancer immunotherapy

F. Garrido, P. thor Straten, 2016, Journal of Immunotherapy for Cancer.

Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes

K. Grønbæk, A. Stenzl, J. Hennenlotter, 2013, Oncoimmunology.

The capacity of CD4+ Vγ9Vδ2 T cells to kill cancer cells correlates with co-expression of CD56.

S. R. Pedersen, I. Svane, P. thor Straten, 2021, Cytotherapy.

Immune-suppressive properties of the tumor microenvironment

J. Becker, D. Schrama, P. thor Straten, 2013, Cancer Immunology, Immunotherapy.

Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression

H. Hasselbalch, P. thor Straten, S. Vidal, 2022, Frontiers in Immunology.

High frequency of T cells specific for cryptic epitopes in melanoma patients

S. Hadrup, Ö. Met, R. Lyngaa, 2013, Oncoimmunology.

Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

I. Svane, R. Andersen, P. thor Straten, 2013, Clinical Cancer Research.

Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients.

J. Becker, I. Svane, P. thor Straten, 2009, The Journal of clinical investigation.

The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines

J. Becker, I. Svane, P. thor Straten, 2009, Cancer Immunology, Immunotherapy.

RhoC a new target for therapeutic vaccination against metastatic cancer

I. Svane, P. thor Straten, M. Andersen, 2008, Cancer Immunology, Immunotherapy.

Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution.

I. Nookaew, J. Becker, J. Gehl, 2016, Cell metabolism.

Ecto‐ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas

J. Zeuthen, P. thor Straten, K. Dzhandzhugazyan, 1998, FEBS letters.

Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model

Ö. Met, P. thor Straten, M. Idorn, 2018, Oncoimmunology.

Mitochondrial-Linked De Novo Pyrimidine Biosynthesis Dictates Human T-Cell Proliferation but Not Expression of Effector Molecules

L. Rasmussen, Ö. Met, P. thor Straten, 2021, Frontiers in Immunology.

Expression of stress-induced MHC class I related chain molecules on human melanoma.

J. Becker, E. Bröcker, T. Spies, 2002, The Journal of investigative dermatology.

The Immunogenicity of the hTERT540-548 Peptide in Cancer

I. Svane, L. Sengeløv, P. thor Straten, 2008, Clinical Cancer Research.

MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells

J. Becker, L. Rasmussen, M. Donia, 2019, Cancer Immunology Research.

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients

M. Donia, I. Svane, T. Borch, 2014, Journal of Immunotherapy for Cancer.

Longitudinal Analysis of MART‐1/HLA‐A2‐Reactive T Cells Over the Course of Melanoma Progression

J. Becker, L. Pedersen, D. Schrama, 2003, Scandinavian journal of immunology.

Differential expression of inhibitory or activating CD94/NKG2 subtypes on MART-1-reactive T cells in vitiligo versus melanoma: a case report.

J. Becker, L. Pedersen, E. Bröcker, 2002, The Journal of investigative dermatology.

Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients.

J. Becker, L. Pedersen, D. Schrama, 2001, Cancer research.

In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes.

J. Becker, P. Guldberg, J. Zeuthen, 1999, Journal of immunology.

Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer

L. Sengeløv, P. thor Straten, M. Idorn, 2014, Cancer Immunology, Immunotherapy.

Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines

J. Zeuthen, P. thor Straten, T. Seremet, 1997, International journal of cancer.

mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma

I. Svane, T. Borch, Ö. Met, 2016, Oncoimmunology.

Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial

H. Rammensee, K. Brasso, M. Røder, 2020, Journal for ImmunoTherapy of Cancer.

TAM Receptor Inhibition–Implications for Cancer and the Immune System

P. thor Straten, Marlies J. W. Peeters, Pia Aehnlich, 2021, Cancers.

TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting

P. thor Straten, Marlies J. W. Peeters, Anne Rahbech, 2019, Cancer Immunology, Immunotherapy.

Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease

I. Svane, M. Pedersen, P. thor Straten, 2014, Cancer Immunology, Immunotherapy.

Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones

J. Zeuthen, P. thor Straten, K. Dzhandzhugazyan, 1999, Cancer Immunology, Immunotherapy.

Differential modulation by interferon γ of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens

J. Zeuthen, P. thor Straten, A. Kirkin, 1996, Cancer Immunology, Immunotherapy.

Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma.

J. Becker, E. Bröcker, J. Zeuthen, 1996, The Journal of clinical investigation.

Persistence of survivin specific T cells for seven years in a melanoma patient During domplete remission

J. Gehl, P. thor Straten, P. Geertsen, 2006, Cancer biology & therapy.

Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8+ T Cells

P. thor Straten, Marlies J. W. Peeters, T. Seremet, 2021, Vaccines.

Identical T-cell receptor transcripts in multiple melanoma metastases.

J. Becker, E. Bröcker, D. Schrama, 2002, Cancer research.

Mutational analysis of oncogenes and tumor suppressor genes in human cancer using denaturing gradient gel electrophoresis.

P. Guldberg, J. Zeuthen, P. thor Straten, 2002, Methods in molecular medicine.

Exercise: A new role for an old tool

P. thor Straten, M. Idorn, 2016, Molecular & cellular oncology.

Integrating Proteomic and Functional Genomic Technologies in Discovery-driven Translational Breast Cancer Research*

Lars Bolund, Jiri Bartek, Peter Roepstorff, 2003, Molecular & Cellular Proteomics.

Anti-melanocyte T cell responses - methodology versus biology.

J. Becker, P. Guldberg, P. thor Straten, 2000, The Journal of investigative dermatology.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

S. H. van der Burg, J. Castle, H. Rammensee, 2019, Molecular & cellular proteomics : MCP.

Cytotoxic T cells.

Mads Hald Andersen, David Schrama, J. Becker, 2006, The Journal of investigative dermatology.

Longitudinal Studies of Clonally Expanded CD8 T Cells Reveal a Repertoire Shrinkage Predicting Mortality and an Increased Number of Dysfunctional Cytomegalovirus-Specific T Cells in the Very Elderly1

G. Pawelec, S. Hadrup, B. Johansson, 2006, The Journal of Immunology.

Transfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2.

I. Svane, Ö. Met, P. thor Straten, 2016, Methods in molecular biology.

Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo

P. thor Straten, M. Idorn, Gitte Holmen Olofsson, 2020, International journal of molecular sciences.

Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters

I. Svane, P. thor Straten, M. Andersen, 2008, Cancer Immunology, Immunotherapy.

Broadening the repertoire of melanoma-associated T-cell epitopes

M. Donia, I. Svane, S. Hadrup, 2015, Cancer Immunology, Immunotherapy.

Actively personalized vaccination trial for newly diagnosed glioblastoma

J. Castle, H. Rammensee, S. Stevanović, 2018, Nature.

Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity.

M. Donia, I. Svane, P. Fagone, 2015, Cancer research.

Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?

P. thor Straten, Gitte Holmen Olofsson, Ana Micaela Carnaz Simões, 2021, Cancers.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

S. H. van der Burg, J. Castle, H. Rammensee, 2018, Molecular & cellular proteomics : MCP.

Detection of mutations in GC-rich DNA by bisulphite denaturing gradient gel electrophoresis.

P. Guldberg, J. Zeuthen, A. Platz, 1998, Nucleic acids research.

Immunological tumor destruction in a murine melanoma model by targeted LTα independent of secondary lymphoid tissue

J. Becker, T. Schumacher, D. Schrama, 2007, Cancer Immunology, Immunotherapy.

T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells

S. Aamdal, G. Kvalheim, G. Gaudernack, 2007, Cancer Immunology, Immunotherapy.

HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer

J. Becker, P. thor Straten, M. Andersen, 2006, Journal of Translational Medicine.

Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site

P. thor Straten, M. Idorn, 2018, Cells.

Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016

J. Taube, P. Ascierto, G. Ciliberto, 2017, Journal of Translational Medicine.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma*

S. H. van der Burg, J. Castle, H. Rammensee, 2018, Molecular & Cellular Proteomics.

More tricks with tetramers: a practical guide to staining T cells with peptide–MHC multimers

Mark Peakman, M. Donia, I. Svane, 2015, Immunology.

Immunogenicity of HLA-A1-restricted peptides derived from S100A4 (metastasin 1) in melanoma patients

D. Schrama, C. Vetter-Kauczok, P. thor Straten, 2009, Cancer Immunology, Immunotherapy.

Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.

I. Svane, S. Hadrup, P. thor Straten, 2011, Blood.

T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors

J. Becker, S. Hadrup, P. Nghiem, 2014, Clinical Cancer Research.

Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture.

J. Becker, P. Guldberg, J. Zeuthen, 2000, Clinical immunology.

Peptide–MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations

Andrew K. Sewell, Mark Peakman, Barbara Szomolay, 2018, The Journal of Immunology.

T-cell clonotypes in cancer

J. Becker, D. Schrama, P. thor Straten, 2004, Journal of Translational Medicine.

In situ T cells in melanoma

J. Becker, P. Guldberg, J. Zeuthen, 1999, Cancer Immunology, Immunotherapy.

Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.

Mads Hald Andersen, Julie Gehl, J. Becker, 2003, Seminars in cancer biology.

Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: A novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma

P. Guldberg, K. Grønbæk, J. Zeuthen, 1997, International journal of cancer.

Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma

J. Becker, S. Ugurel, E. Bröcker, 2012, Cancer Immunology, Immunotherapy.

Therapeutic Cancer Vaccines in Combination with Conventional Therapy

Mads Hald Andersen, I. Svane, P. thor Straten, 2010, Journal of biomedicine & biotechnology.

Mitochondrial-linked de novo pyrimidine synthesis as a regulator of T cell responses

P. thor Straten, Marlies J. W. Peeters, C. Desler, 2023, Immunometabolism.

The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays

A. Mackensen, Tania T. Køllgaard, C. Gouttefangeas, 2007, Cancer Immunology, Immunotherapy.

Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue.

J. Becker, E. Bröcker, W. Fischer, 2001, Immunity.

Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment

M. Donia, S. Hadrup, P. thor Straten, 2012, Cancer Microenvironment.

Detection and characterization of alpha-beta-T-cell clonality by denaturing gradient gel electrophoresis (DGGE).

P. Guldberg, J. Zeuthen, I. Saeterdal, 1998, BioTechniques.

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

M. Donia, I. Svane, S. Hadrup, 2012, Journal of Translational Medicine.

Immunological consequences of the sentinel lymph-node biopsy--lessons from a melanoma patient.

J. Becker, L. Pedersen, E. Bröcker, 2003, The Lancet. Oncology.

Cancer treatment: the combination of vaccination with other therapies

J. Becker, I. Svane, D. Schrama, 2008, Cancer Immunology, Immunotherapy.

The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses.

J. Becker, P. thor Straten, M. Andersen, 2004, The Journal of investigative dermatology.

Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors

J. Becker, I. Svane, P. thor Straten, 2010, Cancer Immunology, Immunotherapy.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

S. H. van der Burg, J. Castle, H. Rammensee, 2019, Molecular & cellular proteomics : MCP.

First in man study: Bcl-Xl_42-CAF®09b vaccines in patients with locally advanced prostate cancer

M. Donia, I. Svane, S. Hadrup, 2023, Frontiers in Immunology.

Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy.

M. Donia, I. Svane, N. Larsen, 2013, Vaccine.

Changes in Peripheral Blood Level of Regulatory T cells in Patients with Malignant Melanoma During Treatment with Dendritic Cell Vaccination and Low‐dose IL‐2

P. thor Straten, M. Andersen, M. Brimnes, 2011, Scandinavian journal of immunology.

Expansion With IL-15 Increases Cytotoxicity of Vγ9Vδ2 T Cells and Is Associated With Higher Levels of Cytotoxic Molecules and T-bet

P. thor Straten, Gitte Holmen Olofsson, Ana Micaela Carnaz Simões, 2020, Frontiers in Immunology.

A case of lymphoblastoid natural killer (NK)‐cell lymphoma: association with the NK‐cell receptor complex CD94/NKG2  and TP53 intragenic deletion

K. Grønbæk, N. E. Hansen, P. Johansen, 2002, The British journal of dermatology.

(GT)n Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation

H. Sengeløv, T. Klausen, P. Brændstrup, 2016, PloS one.

Genetically engineered cell factories produce glycoengineered vaccines that target antigen-presenting cells and reduce antigen-specific T-cell reactivity.

H. Wandall, B. Petersen, A. Pedersen, 2018, The Journal of allergy and clinical immunology.

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

I. Svane, H. Hasselbalch, Ö. Met, 2018, Leukemia.

P29. T-cell responses to oncogenic Merkel cell polyomavirus proteins distinguish Merkel cell carcinoma patients from healthy donors

P. Nghiem, D. Schrama, O. Met, 2014, Journal of Immunotherapy for Cancer.

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

M. Donia, I. Svane, S. Hadrup, 2012, Journal of Translational Medicine.

High Intensity Aerobic exercise training and Immune cell Mobilization in patients with lung cancer (HI AIM)—a randomized controlled trial

G. Persson, P. thor Straten, A. Vinther, 2022, BMC Cancer.

Preferential usage of T-cell receptor alpha beta variable regions among tumor-infiltrating lymphocytes in primary human malignant melanomas.

J. Zeuthen, K. Hou‐Jensen, P. thor Straten, 1994, International journal of cancer.

Analysis of T cell receptor alpha beta variability in lymphocytes infiltrating melanoma primary tumours and metastatic lesions.

J. Schøller, J. Zeuthen, K. Drzewiecki, 1994, Cancer immunology, immunotherapy : CII.

Preferential usage of T-cell receptor alpha beta variable regions among tumor-infiltrating lymphocytes in primary human malignant melanomas.

J. Schøller, J. Zeuthen, K. Hou‐Jensen, 1994, International journal of cancer.

Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016

J. Taube, P. Ascierto, G. Ciliberto, 2017, Journal of Translational Medicine.

Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution.

I. Nookaew, J. Becker, J. Gehl, 2016, Cell metabolism.

Characterization of Ex Vivo Expanded Tumor Infiltrating Lymphocytes from Patients with Malignant Melanoma for Clinical Application

I. Svane, P. thor Straten, M. Andersen, 2011, Journal of skin cancer.

Comparative delineation of T cell clonotypes in coexisting syngeneic B16 melanoma

J. Becker, P. Guldberg, J. Zeuthen, 2000, Cancer Immunology, Immunotherapy.

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.

B. Seliger, M. Lauss, M. Donia, 2017, Cancer research.

Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

M. Donia, I. Svane, H. Hendel, 2016, Clinical Cancer Research.

Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells

Ö. Met, P. thor Straten, E. Martinenaite, 2024, Oncoimmunology.